{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:38:56Z","timestamp":1794713936237,"version":"4.9.1"},"reference-count":14,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03785964\">NCT03785964<\/jats:ext-link>\n                    ) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis.\n                  <\/jats:p>","DOI":"10.1200\/jco-25-00582","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:59:38Z","timestamp":1760990378000},"page":"3646-3651","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03785964","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-7922","authenticated-orcid":true,"given":"Ravin","family":"Ratan","sequence":"first","affiliation":[{"name":"University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-8356","authenticated-orcid":true,"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[{"name":"University of Heidelberg; Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-0405","authenticated-orcid":true,"given":"Thierry","family":"Alcindor","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":true,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[{"name":"Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7549-3338","authenticated-orcid":true,"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Federman","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Orthopedics, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-4349","authenticated-orcid":true,"given":"Nam Q.","family":"Bui","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"D'Amato","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-8710","authenticated-orcid":true,"given":"Richard F.","family":"Riedel","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-4773","authenticated-orcid":true,"given":"Steven","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant","family":"Chawla","sequence":"additional","affiliation":[{"name":"Sarcoma Oncology Center, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-8465","authenticated-orcid":true,"given":"Allison","family":"Lim","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Inc, Stamford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0967-7330","authenticated-orcid":true,"given":"Brad","family":"Tumminello","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Inc, Stamford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Oton","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Inc, Stamford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Chu","sequence":"additional","affiliation":[{"name":"Sumptuous Data Sciences, Monmouth Junction, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfan","family":"Zhou","sequence":"additional","affiliation":[{"name":"SpringWorks Therapeutics, Inc, Stamford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-0119","authenticated-orcid":true,"given":"Mrinal","family":"Gounder","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805052"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30276-1"},{"key":"e_1_3_10_4_2","volume-title":"SpringWorks Therapeutics, Inc. OGSIVEO\u00ae (Nirogacestat). Full Prescribing Information","year":"2023","unstructured":"SpringWorks Therapeutics, Inc. OGSIVEO\u00ae (Nirogacestat). Full Prescribing Information. 2023"},{"key":"e_1_3_10_5_2","unstructured":"US Food and Drug Administration: FDA approves nirogacestat for desmoid tumors. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nirogacestat-desmoid-tumors"},{"key":"e_1_3_10_6_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma. Version 1.2025. May 2 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210140"},{"key":"e_1_3_10_8_2","volume-title":"Declaration of Helsinki. Recommendations Guiding Doctors in Clinical Research","author":"18th World Medical Assembly","year":"1964","unstructured":"18th World Medical Assembly: Declaration of Helsinki. Recommendations Guiding Doctors in Clinical Research. Helsinki, Finland, 1964"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02592-0"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32555"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S362694"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2340"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000349918"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2025.1915"},{"key":"e_1_3_10_15_2","unstructured":"European Commission: SpringWorks Therapeutics. Ogsiveo (nirogacestat). August 18 2025. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1932.htm"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:59:33Z","timestamp":1764025173000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":14,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1200\/JCO-25-00582"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00582","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}